The Effect of EDP on Diaphragmatic Function and Neural Respiratory Drive in Patient With AECOPD

Zhujiang Hospital40 enrolled

Overview

Chronic Obstructive Pulmonary Disease (COPD) is a common respiratory disease characterized by airflow limitation that is progressive and not fully reversible. Patients with acute exacerbation of COPD must be hospitalized, as for further increase in airway resistance, pulmonary alveolar excessive expansion, diaphragm fatigue and neural respiratory drive. In recent years, Pulmonary rehabilitation is recognized as a core component in the comprehensive management of COPD, EDP as a means of rehabilitation can alleviate diaphragmatic fatigue, improve ventilation function, reduce the neural respiratory drive in patients with COPD during hospitalization, but still lack of evidence based medicine. Surface EMGdi can accurately evaluate neural respiratory drive, its detection is non-invasive, simple and safety .Therefore,Neural respiratory drive by surface EMGdi can be used as an important index for evaluating the therapeutic efficacy of AECOPD patients during hospitalization. In the present study, about 40 patients with COPD will be recruited as research subjects .And the investigators aim to explore the effect of EDP on diaphragmatic function and neural respiratory drive in patient with AECOPD.Contrast analysis will be conducted to evaluate the effects of EDP on patients with AECOPD, which may provide a reasonable basis for the clinical application of EDP to AECOPD patients.

Patients with AECOPD will participate in a rehabilitation program for one week. Participants in the proposed study will be randomly divided into two intervention groups:controlgroup and EDP therapy group. Before using EDP,the investigators will measure the relevant parameters of lung volume , diaphragm electromyogram, diaphragm activity and other basline index. Then EDP will be applied to investigate the effects of EDP on the above mentioned respiratory mechanics parameters.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Interventions

control groupDEVICE

No EDP treatment

EDPDEVICE

Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with pulmonary function test of forced expiratory volume at one second (FEV1)/forced vital capacity(FVC) \< 70% after inhalation of bronchial dilation agent. * Patients in a clinically acute exacebation state. Exclusion Criteria: * Patients were excluded if they had evidence of pneumothorax or mediastinal emphysema and pacemaker installed. * Patients with acute cardiovascular event and severe cor pulmonale. * Patients with poor compliance. * An Other causes of diaphragmatic dysfunction.

Outcomes

Primary Outcomes

Diaphragmatic function(composite outcome measure)

Diaphragmatic function can be assessed by surface diaphragm electromyogram (EMGdi), which reflect the physiological activity of the diaphragm and indicate functional status of the neural respiratory drive.

Time frame: Change from baseline in diaphragm electromyogram.(1 week later)

Secondary Outcomes

Degree of dyspnea(composite outcome measure)

Difference in the degree of dyspnea can be measured by borg index.

Time frame: Change from baseline in degree of dyspnea.(1 week later)

Pulmonary Function(composite outcome measure)

Pulmonary function is measured using a spirometer(PonyFX 229, Cosmed, Rome, Italy) that is calibrated daily.The FEV1 and percent-of-predicted FEV1, FVC and percent-of-predicted FVC which are presented in one report are used to evaluate Pulmonary Function.

Time frame: Change from baseline in pulmonary function.(1 week later)

Exercise Capacity(composite outcome measure)

Exercise capacity is evaluated using the 6-min walking distance (6MWD) according to American Thoracic Society guidelines.

Time frame: Change from baseline in exercise capacity.(1 week later)

Diaphragm activity(composite outcome measure)

The degree of activity of the left and right diaphragmatic muscles in the general breath and deep breath were measured respectively.

Time frame: Change from baseline in diaphragm activity.(1 week later)

Diaphragm thickness(composite outcome measure)

The changes of diaphragm thickness of the left and right diaphragmatic muscles in the breath were measured respectively.

Time frame: Change from baseline in diaphragm thickness.(1 week later)

Inspiratory muscle function(composite outcome measure)

Currently, the maximal inspiratory pressure (PImax) and maximal expiratory pressures(PEmax) are measured by a digital manometer (AZ-8205, AZ Instrument, Taichung City, Taiwan)and combined to evaluate inspiratory muscle function.

Time frame: Change from baseline in inspiratory muscle function.(1 week later)